Evolution of Stability Guidelines: From the ICH Q1A-F Series to the Consolidated ICH Q1 Guideline

Fernanda Maldonado Benítez - *Analytical Services*



Stability studies are essential to monitor and ensure the quality of Finished Pharmaceutical Products (FPPs) and Active Pharmaceutical Ingredients (APIs) over time, considering the impact of environmental conditions, excipient interactions, packaging, and container-closure systems[1]. The regulatory framework for these studies was established through stability guidelines developed by the International Council for Harmonization (ICH) and the World Health Organization (WHO). The first ICH Q1A guideline, adopted in 1993 and revised in the early 2000s, was later expanded with supplementary guidelines (Q1B–Q1F) to address specific aspects of stability testing[2]. In April 2025, ICH released a draft consolidated guideline, ICH Q1: Stability Testing of Drug Substances and Drug Products, which unifies and modernizes these documents into a single, comprehensive standard applicable to all product types[3,4]. The revision responds to the need to simplify and modernize stability requirements, resolve gaps and ambiguities in the previous guidance, and align with scientific and technological advancements. It will supersede the ICH Q1A-Q1F Stability guidelines and ICH Q5C: Quality of Biotechnological Products- Stability Testing of Biotechnological/Biological Products[5] . It is currently under Step 3 for public consultation.

The consolidated ICH Q1 guideline introduces both structural and content-related changes. Structurally, it organizes stability requirements into 18 sections and three annexes, covering the entire life cycle of stability testing- from stress and forced degradation studies in early development, to post-approval commitments and lifecycle management. This unified format provides a single reference with greater internal consistency.

From a content perspective, the draft broadens stability data expectations beyond initial marketing applications to include other regulatory submissions, while expanding the technical scope to cover the full spectrum of pharmaceutical products- from small molecules to vaccines and other advanced therapies. Other new considerations that this draft introduces are the evaluation of process intermediates (section 4), to justify hold times and intermediate storage conditions; guidance on how to scientifically justify temporary off-label storage conditions (section 10); and requirements to ensure product safety and efficacy under real- use conditions (section 6). It also addresses explicit stability expectations for critical auxiliary materials, covering reference standards, novel or non-traditional excipients, and adjuvants by clarifying the need to justify the assigned period of use, periodically verify or re-evaluate their stability, and implement quality control and monitoring where they may impact overall product stability. Moreover, the draft integrates life cycle management principles as previously covered by ICH Q10: Pharmaceutical Quality System[6] and Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management (Section 15)[3,7]. It expands the scope of stability commitments required at the time of authorization and introduces a full lifecycle management approach, from initial development through to discontinuation. It establishes that the management

of stability should encompass not only primary studies to define shelf-life or retest period but also commitment stability studies, especially when approval is sought with incomplete long-term data (e.g., reduced protocols supported by scientific evidence), ongoing studies as part of the Pharmaceutical Quality System (PQS) and stability studies to support post-approval changes. This broader view is reflected in the revised approach to photostability testing (section 7, previously covered in ICH Q1B: Photostability Testing of New Drug Substances and Products[8]): the perspective shifts from a narrowly focused guideline designed to mainly meet registration requirements to one that embeds photostability throughout the entire product lifecycle. Importantly, Section 14 addresses transient temperature excursions outside of labelled storage conditions, which were previously managed only through the PQS or local regulations. The guideline now establishes that stability data can be used to justify the impact of an excursion on a drug substance or drug product. Where sufficient knowledge of the degradation pathway exists, statistical evaluation or predictive modelling may also be applied to assess the impact, provided the data fits an appropriate model. These additions fill critical gaps in the earlier guidelines and brings stability expectations in line with current scientific progress and regulatory needs.

On the other hand, by integrating the modern quality framework such as ICH Q8-Q12 and Q14, it brings a more flexible, science-based approach to stability planning. Instead of a rigid approach, manufacturers can develop their own stability protocols, particularly when robust scientific evidence supports a reduced design. Annex 1 reinforces this principle by extending the concept of reduced protocols beyond the traditional bracketing and matrixing approaches of ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products[9]. That said, the key is scientific justification. It is not about doing fewer tests for convenience, but rather about applying risk - and knowledge - driven strategies focused on Critical Quality Attributes (CQAs) to make stability studies more efficient. This commitment also extends to how the data is evaluated. While the guideline retains familiar statistical methods previously covered in Q1E: Evaluation of Stability Data (ICH2, 2003), it encourages the use of enhanced tools (e.g. Bayesian methods that integrate prior knowledge into expiry dating) (Section 13). This stance ties back to Quality by Design (QbD): the more knowledge and data there is, the more confidently one can predict stability outcomes [3] .

In recent years, health authorities have seen an increase in applicants using tools to predict stability outcomes, supplementing the traditional real-time studies[3]. Annex 2 of ICH Q1 recognizes modern techniques, such as kinetic modeling and stability scenario simulation. The Accelerated Stability Assessment Program (ASAP) is a predictive approach, based on the humidity-modified Arrhenius kinetics, that enables a rapid estimation of the chemical stability of pharmaceutical products. Instead of waiting months or years for traditional stability studies, it applies accelerated conditions, such as elevated temperature and humidity, to predict shelf life and support early formulation/packaging decisions[10]. The protocol involves several conditions designed to model the effects of relative humidity and temperature in a typical 2–4-week time frame. It recognizes that both temperature and humidity can accelerate drug degradation, especially in hydrolysis-sensitive solids, and it uses a modified Arrhenius equation where a humidity term has been added to determine parameters such as reaction frequency and activation energy, which can be later used to extrapolate stability under normal storage conditions. It goes hand in hand with forced degradation studies (section 2), which help identify critical degradation mechanisms that can later be used to model the kinetics of relevant degradation processes [11].



Nevertheless, every stability model carries inherent risk, because it extrapolates beyond the available data. Therefore, regulatory submissions must include a risk assessment when models are used to establish shelf-life or retest periods. Such assessments should follow ICH Q9 (Quality Risk Management), requiring that risks be identified, evaluated, and mitigated through appropriate strategies. Predictive modeling must be scientifically justified, validated and continuously verified with real-time data. Applicants also are responsible for identifying stability-relevant Critical Quality Attributes (CQAs) to be included in the model; any attributes excluded must be justified and potential impact of unexpected changes in non-modelled attributes should be considered as part of risk management. This risk management must be continuous throughout the lifecycle and integrated into the PQS, consistent with ICH Q10. Overall, Annex 2 provides a formal and harmonized framework that acknowledges predictive tools as complementary—rather than substitutes—for real-time studies, while also recognizing the inherent risks of modeling and the need to actively manage them.

Finally, Annex 3 provides stability guidance on advanced therapy medicinal products (ATMPs)[2], including cell therapies, gene therapies, and tissue-engineered products, previously covered by ICH[5]

Q5C: Quality of Biotechnological Products - Stability Testing of Biotechnological/Biological Products. It's no longer a stand-alone document, but now forms part of the guideline for stability testing, addressing challenges such as the short shelf-life of some ATMPs, cryopreserved products, unique potency assays for live or highly complex components (live cells, virus/bacteria-based products, DNA/RNA based products, etc.), and products that are particularly sensitive to handling and transportation. This formal introduction of ATMPs into the internationally harmonized stability framework reduces regulatory uncertainty and facilitates the global development and approval of these therapies.

How does the consolidation of the ICH Q1 guideline impact pharmaceutical companies? It poses both opportunities and challenges. On one hand, it reduces regulatory fragmentation by replacing Q1A-F and Q5C with a single, harmonized standard, which will facilitate global submissions. On the other hand, it calls upon industry to justify everything through a scientific and risk-based approach. Stability studies are no longer check-box exercises, but must be justified through prior knowledge, QbD, and integration into the PQS. The expanded scope covering ATMPs and drug-device combinations requires companies to adopt broader and more flexible stability strategies, and the formal inclusion of predictive modeling and adaptive protocols gives regulatory legitimacy to tools that were already being used but lacked common framework, allowing for reduced development timelines and providing clear guidance for biological products and innovative therapies.

Overall, the guideline shifts stability from a static regulatory requirement to a more dynamic and flexible element of quality management, pushing the industry toward more knowledge-driven and globally harmonized practices.

References

1. González-González, O.; Ramirez, I. O.; Ramirez, B. I.; O'Connell, P.; Ballesteros, M. P.; Torrado, J. J.; Serrano, D. R. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics 2022, 14 (11), 2324. https://doi.org/10.3390/pharmaceutics14112324.
2. Joanne S. Eglovitch. ICH Releases Overhauled Stability Guideline for Consultation. Regulatory News.
3. Nawaz, S. ICH Revises Q1 Guideline, Advancing Stability Testing Standards. Pharmaceutical Online. https://www.pharmaceuticalonline.com/doc/ich-revises-q-guideline-advancing-stability-testing-standards-0001 (accessed 2025-08-19).
4. ICH. ICH Q1: Stability Testing of Drug Substances and Drug Products-Step 2; 2025.
5. ICH. ICH Q5C: Stability Testing of Biotechnological/Biological Products; 1995.
6. ICH. ICH Q10: Pharmaceutical Quality System; 2008.
7. ICH. ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; 2019.
8. ICH. ICH Q1B: Photostability Testing of New Drug Substances and Products; 1996.
9. ICH. ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products; 2002.
10. Malcolm, L. Chapter 12 - Accelerated Stability Assessment Program (ASAP) Applications in a Postapproval Environment. In Accelerated Predictive Stability; Qiu, F., Scrivens, G., Eds.; Academic Press: Boston, 2018; pp 287–304. https://doi.org/https://doi.org/10.1016/B978-0-12-802786-8.00012-7.
11. Waterman, K. C.; Colgan, S. T. A Science-Based Approach to Setting Expiry Dating for Solid Drug Products. Regulatory Rapporteur 2008, 5 (7), 9–14.